MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by HORN, A. S.
Right arrow Articles by SNYDER, S. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HORN, A. S.
Right arrow Articles by SNYDER, S. H.

Molecular Pharmacology, Vol 7, 66-80, Copyright © 1971 by the American Society for Pharmacology and Experimental Therapeutics

Catecholamine Uptake by Synaptosomes from Rat Brain

Structure-Activity Relationships of Drugs with Differential Effects on Dopamine and Norepinephrine Neurons

ALAN S. HORN 1, JOSEPH T. COYLE 1, and SOLOMON H. SNYDER 1

1 Departments of Pharmacology and Experimental Therapeutics and Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland 212O5

A number of centrally active drugs, including antiparkinsonian agents, antihistamines, tricyclic antidepressants, and phenothiazines, inhibit catecholamine uptake into synaptosomes prepared from various areas of rat brain. Many of these drugs have markedly differing affinities for the dopamine neurons of the corpus striatum as compared to the norepinephrine neurons in other brain regions. All drugs examined inhibit catecholamine uptake into hypothalamic synaptosomes competitively, but are noncompetitive inhibitors in the corpus striatum. In both brain areas, uptake inhibition appears to be reversible. In a series of drugs, certain structural features are related to the relative selectivity toward norepinephrine or dopamine neurons. Replacement of an alkylamino side chain by a tropine ring system enhances affinity for the dopamine neurons, as does a relative lack of constraint of the aromatic ring. The antidepressant drugs imipramine and amitriptyline are affected oppositely by N-demethylation. While N-demethylation of imipramine increases its affinity for hypothalamic catecholamine synaptosomes 20-fold, N-demethylation of amitriptyline reduces the inhibition of hypothalamic catecholamine uptake 24-fold. Such structure-activity relationships may facilitate the development of drugs with a high degree of selectivity, respectively, for dopamine and norepinephrine neurons.

Note:
ACKNOWLEDGMENTS We wish to thank the following companies for donations of drugs, listed alphabetically: amytriptyline hydrochloride (Merck Sharp & Dohme); benztropine mesylate (Merck Sharp & Dohme); biperiden hydrochloride (Knoll Pharmaceutical Company); BS 6825, 7039, 7042, 7715, and 7723 (Brocades-Stheeman); carbinoxamine maleate (McNeil Laboratories, Inc.); carphenazine dimaleate (Wyeth Laboratories, Inc.); chlorcyclizine hydrochloride (Burroughs Wellcome and Company); chlorpheniramine maleate (Schering Corporation); chlorpromazine hydrochloride (Smith Kline & French Laboratories); cyclizine hydrochloride (Burroughs Wellcome and Company); cycrimine hydrochloride (Eli Lilly and Company); deptropine citrate (Brocades-Stheeman); desipramine hydrochloride (Geigy Chemical Corporation); diethazine hydrochloride (Smith Kline & French Laboratories); diphenhydramine hydrochloride (Parke Davis and Company); diphenylpyraline hydrochloride (Smith Kline & French Laboratories); doxepin hydrochloride (Charles Pfizer and Company); ethopropazine hydrochloride (Warner-Lambert Research Institute); fenazoxine hydrochloride (Riker Laboratories); hyoscine hydrochloride (Smith Kline & French Laboratories); imipramine hydrochloride (Geigy Chemical Corporation); mepazine hydrochloride (Chemische Fabrik Promonta G.m.b.H.); methixene hydrochloride (Dr. A. Wander, Ltd); nortriptyline hydrochloride (Eli Lilly and Company); orphenadrine hydrochloride (Riker Laboratories); phenindamine tartrate (Hoffman-La Roche, Inc.); procyclidine hydrochloride (Burroughs Wellcome and Company); propiomazine hydrochloride (Wyeth Laboratories, Inc.); protriptyline hydrochloride (Merck Sharp & Dohme); pyrathiazine hydrochloride (Upjohn Company); trihexphenidyl hydrochloride (Lederle Laboratories). We would like to thank Dr. Donald Coffey for his advice on some of the kinetic aspects of this work, and also Miss Molly Ruble for her technical assistance.

Submitted on August 12, 1970




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
C. K. Jones and H. E. Shannon
Muscarinic Cholinergic Modulation of Prepulse Inhibition of the Acoustic Startle Reflex
J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 1017 - 1023.
[Abstract] [Full Text]


Home page
ScienceHome page
C. Lee, J. Javitch, and S. Snyder
Recognition sites for norepinephrine uptake: regulation by neurotransmitter
Science, May 6, 1983; 220(4597): 626 - 629.
[Abstract] [PDF]


Home page
ScienceHome page
C de Montigny and G. Aghajanian
Tricyclic antidepressants: long-term treatment increases responsivity of rat forebrain neurons to serotonin
Science, December 22, 1978; 202(4374): 1303 - 1306.
[Abstract] [PDF]


Home page
ScienceHome page
F. Crews and C. Smith
Presynaptic alpha-receptor subsensitivity after long-term antidepressant treatment
Science, October 20, 1978; 202(4365): 322 - 324.
[Abstract] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1971 by the American Society for Pharmacology and Experimental Therapeutics